Objective-Vascular calcification is a characteristic feature of atherosclerosis, diabetes mellitus, and end-stage renal disease.
V ascular calcification, namely aberrant calcium deposition in the vessel wall, reduces elasticity and compliance of the vessel wall. It is a well-known predictive risk factor of subsequent cardiovascular mortality. [1] [2] [3] Vascular calcification has now been recognized as an active cell-regulated process resembling bone modeling, rather than simply passive calcium deposition. [4] [5] [6] [7] [8] [9] [10] Several cell types are involved in this process, including vascular smooth muscle cells (VSMC), which undergo osteogenic differentiation and calcification. [4] [5] [6] [7] [8] [9] [10] We have demonstrated that runt-related transcription factor 2 (Runx2), the key osteogenic regulator for osteoblast differentiation and chondrocyte maturation, 11, 12 plays an essential role in regulating osteogenic differentiation of VSMC in vitro 13 and vascular calcification in atherosclerosis in vivo. 14 Furthermore, we have determined that activation of protein kinase B (AKT) is crucial for oxidative stress-induced VSMC calcification through upregulation of Runx2, 13 and constitutively activated AKT promotes VSMC calcification. 15 However, the molecular mechanisms underlying AKT-regulated upregulation of Runx2 and VSMC calcification are unknown. Activation of AKT is regulated by 2 major upstream signals: phosphatidylinositol 3-kinase and phosphatase and tensin homolog (PTEN). PTEN is a protein/lipid phosphatase, which was originally discovered as a tumor repressor. 16, 17 PTEN inactivates AKT by hydrolyzing phosphatidylinositol-3,4,5-trisphosphate. 18 PTEN has been implicated in regulating neointimal smooth muscle cell proliferation and migration. 19, 20 PTEN deficiency in smooth muscle cells activates AKT in the mouse vasculature, [21] [22] [23] which contributes to increased smooth muscle cell proliferation that leads to intimal hyperplasia in mouse vascular development 21, 23 and in response to injury. 22 In atherosclerosis studies, partial inactivation of PTEN does not seem to affect high-fat diet-induced atherosclerosis of the atherogenic ApoE −/− mice, 24 but chemical-induced expression of PTEN was found to be associated with inhibition of highcholesterol diet-induced atherosclerosis in a rabbit model. 25 It is unknown whether PTEN plays a role in regulating vascular calcification. Using the SMC-specific PTEN deletion mice, we determined a causative effect of the PTEN deficiency on vascular calcification, independent of cell proliferation, and elucidated the underlying molecular mechanisms.
One of the known downstream signals regulated by activated AKT is the family of forkhead box O (FOXO) proteins. The FOXO family includes FOXO1, FOXO3, FOXO4, and FOXO6 in mammalian cells. FOXO1, FOXO3, and FOXO4 are ubiquitously expressed, whereas FOXO6 is specifically expressed in brain and liver. [26] [27] [28] [29] Activated AKT phosphorylates FOXOs and leads to exclusion of the FOXOs from the nucleus, which blocks the transcriptional activity of FOXOs. 30 The role of the FOXOs in VSMC calcification is entirely unknown. Previous studies have suggested a potential link between FOXO and Runx2 expression in other cell types. [31] [32] [33] [34] In osteoblasts and human embryonic stem cells, FOXO1 or FOXO3 increases Runx2 expression, whereas other studies suggest that FOXO1 inhibits Runx2 activity in osteoblasts or prostate cancer cells. [31] [32] [33] [34] Therefore, the function of FOXOs in regulating Runx2 expression may be cell type-dependent. In this study, we have determined, for the first time, the function of FOXOs in regulating VSMC calcification and elucidated the role of FOXOs in AKT-regulated upregulation of Runx2 and VSMC calcification.
We have determined that SMC-specific PTEN deletion promoted VSMC calcification in vitro, aortic calcification ex vivo and in vivo, via increased activation of AKT that upregulates Runx2. VSMC calcification induced by the PTEN deficiency is independent of VSMC proliferation. Mechanistically, activation of AKT by PTEN deficiency induces inhibition of FOXO1/3 that led to the upregulation of Runx2. The upregulation of Runx2 occurred post-transcriptionally through inhibiting Runx2 ubiquitination. Using heterozygous SMC-specific PTEN-deficient mice and atherogenic ApoE −/− mice, we have also demonstrated AKT activation, FOXO phosphorylation, and Runx2 ubiquitination in vascular calcification in vivo. Altogether, our studies have provided the first evidence demonstrating a causative effect of SMC-specific PTEN deficiency on vascular calcification and identified a novel function of FOXO1/3 in the regulation of the Runx2 ubiquitination and vascular calcification.
Materials and Methods
The smooth muscle-specific PTEN-deficient mice were generated by crossing PTEN exon 5 floxed mice (PTEN f/f ) 35 with the SM22α-Cre transgenic mice. 14 
Results

Activation of AKT by PTEN Deficiency Promotes Runx2 Upregulation and VSMC Calcification
We have demonstrated that activation of AKT is associated with VSMC calcification in vitro. 13, 15 Using mice with SMC-specific ablation of PTEN, 18 the key upstream negative regulator for AKT activation, we aimed to determine a direct effect of endogenous AKT activation on VSMC calcification. The SMC-specific PTEN deletion mice (PTEN ∆/∆ ) were generated by crossing the PTEN exon 5 floxed mice with SM22Cre transgenic mice. Similar to previous observation, 37 the SM22Cre-mediated PTEN deletion resulted in early death of the PTEN ∆/∆ mice. We and others have reported that osteogenic differentiation of VSMC determines vascular calcification 5, 6, 14 ; therefore, the effect of the PTEN deletion on osteogenic differentiation of VSMC was first characterized using primary VSMC from the PTEN ∆/∆ mice and their control PTEN f/f littermates. The deletion of PTEN in VSMC was demonstrated by Western blot analysis ( Figure 1Aa ). AKT1 was found to be the predominant isoform of AKT in VSMC. The PTEN deletion did not affect the expression of AKT mRNA in VSMC ( Figure 1Ab ); however, it increased activation of AKT1, as indicated by AKT phosphorylation at both serine 473 (S473) and threonine 308 (T308) residues in the PTEN ∆/∆ VSMC cultured in growth media ( Figure 1Aa ). Marked increase in calcification was also observed in PTEN ∆/∆ VSMC cultured in osteogenic media for 3 weeks compared with the PTEN f/f VSMC (Figure 1Ba ), which was further confirmed by quantitative calcium measurement ( Figure 1Bb ). Concurrently, the expression of osteogenic transcription factor Runx2 and Runx2-regulated osteogenic marker genes, including osteocalcin and collagen type I, was increased in the PTEN ∆/∆ VSMC (Figure 1Bc ). Notably, a dramatic increase in the Runx2 protein level was evident in the PTEN ∆/∆ VSMC (Figure 1Bd ). Accordingly, we conclude the PTEN deletion in VSMC constitutively activates AKT and promotes upregulation of Runx2 and osteogenic differentiation of VSMC.
Inhibition of AKT and Runx2 Attenuates Calcification of the PTEN-Deficient VSMC
The definitive role of AKT/Runx2 signaling axis in mediating the PTEN deficiency-induced VSMC calcification was further determined by loss of function studies. Inhibition of AKT activation by an AKT inhibitor abolished calcification of the PTEN ∆/∆ VSMC (Figure 1Ca ), which was associated with inhibition of Runx2 upregulation ( Figure 1Cb ). Furthermore, we found that knockdown of Runx2 by specific small hairpin RNA blocked calcification of PTEN ∆/∆ VSMC (Figure 1Da ). The Runx2 knockdown did not affect AKT phosphorylation ( Figure 1Db ). These data demonstrated that upregulation of Runx2 by activation of AKT is essential for the PTEN deficiency-induced VSMC calcification. Of note, the Runx2 knockdown blocked calcification but did not affect proliferation of the PTEN ∆/∆ VSMC ( Figure I in the online-only Data Supplement), suggesting that the Runx2 upregulation-dependent calcification in the PTEN-deficient VSMC is independent of its effect on VSMC proliferation. 
SMC-Specific PTEN Deletion Promotes Ex Vivo Aortic Calcification
The effect of SMC-specific PTEN deletion on calcification of VSMC in their natural milieu was characterized in an ex vivo aortic ring culture system using descending aortas from PTEN ∆/∆ mice and their control littermates. Immunohistochemical staining with a PTEN-specific antibody demonstrated specific deletion of PTEN in the media, but not in the endothelium (Figure 2A, PTEN arrows) . Histological analysis demonstrated increased medial thickness and decreased smooth muscle α-action, a SMC marker in the PTEN ∆/∆ aortas (Figure 2A ), which is consistent with the previous findings that PTEN regulates proliferation of SMCs. [19] [20] [21] [22] [23] 25 On the other hand, sustained increased phosphorylation of AKT was demonstrated in the PTEN ∆/∆ aorta (Figure 2A ). Similar to the observation with isolated VSMC, aortas from PTEN ∆/∆ mice exhibited intensive calcification after cultured in osteogenic media for 2 weeks (Figure 2B , Alizarin red and Von Kossa), which was associated with decreased smooth muscle α-action and elevated Runx2 ( Figure 2B ). By contrast, vascular calcification was not evident in aortas from the control PTEN f/f littermates under the same conditions ( Figure 2B ). These results demonstrated a direct effect of endogenous activation of AKT by the PTEN deletion in VSMC on upregulation of Runx2 and VSMC calcification.
PTEN Deficiency Upregulates Runx2 by Inhibiting Runx2 Ubiquitination
To determine the molecular mechanism underlying activation of AKT in promoting upregulation of Runx2 and VSMC calcification, we first characterized Runx2 expression in the PTEN ∆/∆ VSMC. The amount of the Runx2 protein was increased during calcification of the PTEN ∆/∆ VSMC (Figure 1Bd ), which was associated with a modest increase in expression of the Runx2 mRNA ( Figure 1Bc ). These observations led us to examine the amount of both Runx2 mRNA and protein in PTEN ∆/∆ VSMC cultured in normal growth media, a basal condition. Under the basal condition, marked increase in the Runx2 protein level was also evident in the PTEN ∆/∆ VSMC (Figure 3Aa ), whereas expression of the Runx2 mRNA is not altered significantly (Figure 3Ab ). Inhibition of de novo protein synthesis by cycloheximide decreased the amount of Runx2 in the control PTEN f/f VSMC ( Figure 3B ) in a time-dependent manner. In contrast, the amount of the Runx2 protein was sustained in the PTEN ∆/∆ VSMC after exposure to cycloheximide for 12 hours, indicating that the PTEN deletion stabilized Runx2 by preventing Runx2 protein from degradation. As ubiquitination mediates degradation of Runx2, 38, 39 we determined the effect of the PTEN deficiency on the Runx2 ubiquitination. The PTEN deletion did not affect the overall expression profile of poly-ubiquitin in VSMC ( Figure 3C , input). However, modification of Runx2 by poly-ubiquitin was markedly decreased in the PTEN ∆/∆ VSMC ( Figure 3C , IP:Runx2), indicating that ubiquitination-mediated degradation of Runx2 was inhibited, which rendered Runx2 stable in the PTEN ∆/∆ VSMC.
AKT Activation Promotes Cytosolic Translocation of FOXO1/FOXO3
The FOXO protein family, one of several known downstream targets of activated AKT, has been associated with expression of Runx2 in osteoblasts, human embryonic stem cells, and prostate cancer cells, although data from these studies are not compelling. [31] [32] [33] [34] We found that FOXO1 and FOXO3a are highly expressed in VSMC compared with FOXO4 ( Figure II in the online-only Data Supplement). The PTEN deficiency in VSMC did not affect the expression of FOXOs mRNA ( Figure II in the online-only Data Supplement) or production of FOXO1/3 proteins ( Figure 4A ). In contrast, phosphorylation of FOXO1 and 3 was dramatically increased in the PTEN ∆/∆ VSMC ( Figure 4A ). As phosphorylation of FOXO has been shown to be associated with nuclear exclusion, 40 we examined the cellular localization of FOXO1/3 in PTEN ∆/∆ VSMC and control PTEN f/f VSMC. The PTEN deletion in VSMC increased cytosolic translocation and decreased nuclear localization of FOXO1/3, which was associated with increased Runx2 in the nuclear ( Figure 4B ). Furthermore, activation of AKT using a lentivirus carrying a constitutively activated AKT similarly promoted cytosolic translocation of FOXO1/3 and abolished their nuclear localization ( Figure 4C) , which was again associated with increased amount of Runx2. These data demonstrate that activation of AKT, either by PTEN deficiency or by overexpression of 
FOXO1/3 Knockdown Inhibits Runx2 Ubiquitination and Promotes VSMC Calcification
We further determined whether inhibition of FOXO1/3 directly affect Runx2 and VSMC calcification by knocking down FOXO1 or FOXO3 in VSMC using specific small hairpin RNA. Knockdown of FOXO1 decreased the expression of FOXO3 in VSMC, and vice versa ( Figure 5A ). Such an observation is consistent with a previous report that FOXO1 and FOXO3 regulate each other in human fibroblasts. 41 Knockdown of FOXO1 or FOXO3 markedly increased the amount of Runx2 detected, without affecting expression of the Runx2 mRNA ( Figure 5A and B) . The effects of FOXO1/3 knockdown on ubiquitination of Runx2 were further determined. Similar to the PTEN deletion, FOXO1 or FOXO3 knockdown in VSMC did not affect the general expression profile of poly-ubiquitin, but inhibited Runx2bound poly-ubiquitin ( Figure 5C ). Furthermore, knockdown of FOXO1 or FOXO3 promoted VSMC calcification, as determined by Alizarin red staining ( Figure 5D ) and quantitative calcium measurement ( Figure 5E ). These data demonstrate that FOXO1/3 negatively regulates the Runx2 stability in VSMC and knockdown of FOXO1/3 phenocopies the PTEN deficiency.
SMC-Specific PTEN Reduction Promotes Vascular Calcification in Mice
The role of AKT/FOXO/Runx2 signaling axis in vascular calcification was further determined in vivo. As the early death of the homozygous SMC-specific PTEN ∆/∆ mice prevented us from carrying out long-term in vivo vascular calcification studies, the heterozygous SMC-specific PTEN-deficient mice (PTEN ∆/+ ) were utilized. The PTEN ∆/+ mice appeared normal as their control littermates (PTEN f/+ ). Decreased PTEN expression was evident in the vasculature of the heterozygous mice ( Figure 6A) . Importantly, the heterozygous SMC-specific PTEN mice fed on a normal chow diet spontaneously developed vascular calcification at 6 months of age ( Figure 6A and B). Alizarin red staining revealed apparent calcium deposition in aortas from the PTEN ∆/+ mice, whereas no calcification was detected in the aortas from control littermates ( Figure 6A ). Quantitative measurement of total calcium content in the aortic tissues further demonstrated increased vascular calcification in the PTEN ∆/+ mice ( Figure 6B) . Moreover, increased vascular calcification in the PTEN ∆/+ mice was associated with increased AKT activation, FOXO phosphorylation, and Runx2 upregulation in the vasculature, as determined by immunostaining ( Figure 6C ) as well as Western blot analyses ( Figure 6D ).
In addition, we determined the AKT/FOXO/Runx2 signaling axis in the atherogenic ApoE −/− mice, which developed atherosclerotic vascular calcification as we demonstrated previously. 14, 36 Consistently, HFD induced upregulation of Runx2 and vascular calcification ( Figure  IV 
Discussion
Runx2 is a key transcriptional regulator required for vascular calcification in vitro and in vivo. Activation of AKT also promotes calcification of VSMC. To uncover underlying mechanisms connecting activation of AKT and upregulation of Runx2 in the development of vascular calcification, we generated a mouse model with sustained AKT activation in VSMC by selective deletion of PTEN, an upstream phosphatase that negatively regulates AKT activation. Our studies reveal a novel causative effect of the SMC-specific PTEN deficiency in promoting vascular calcification. Using VSMC from the SMC-specific PTEN deletion mice, we have also elucidated a new function of PTEN/AKT/FOXO1/3 signaling axis in regulating ubiquitination of Runx2 and vascular calcification. The important role of the AKT/FOXO/Runx2 signaling axis in vascular calcification in vivo has been further demonstrated with the heterozygous SMC-specific PTEN deletion mice and the atherogenic ApoE −/− mice.
As a protein/lipid phosphatase, PTEN has diverse functions in different type of cells; most notable one is its tumor repression activity. In the vasculature, PTEN has been implicated in proliferation, differentiation, and migration of smooth muscle cell [19] [20] [21] [22] [23] 37 ; however, the role of PTEN in vascular calcification is entirely unknown. Our studies with comprehensive approaches using the SMC-specific PTEN deletion VSMC in vitro, aortas ex vivo, and the heterozygous SMC-specific PTEN deletion mice in vivo have strongly supported a causative effect of the PTEN inhibition on vascular calcification. Using an AKT inhibitor, we confirmed that activation of AKT is crucial for calcification of the PTEN-deficient VSMC. Furthermore, we demonstrated that upregulation of Runx2 was required for the calcification of VSMC from the PTEN-deficient mice. Importantly, the Runx2 knockdown was found to only block calcification but not proliferation of the PTEN-deficient VSMC, suggesting that PTEN deficiency-induced Runx2 upregulation promotes osteogenic differentiation of VSMC, which may be independent of its previously reported function in regulating VSMC proliferation, differentiation, and migration. [19] [20] [21] [22] [23] 37 In normal VSMC, the amount of Runx2 detected is low. 42, 43 In the PTEN-deficient VSMC, however, markedly increased Runx2 was evident even under the basal condition. Since we have shown that upregulation of Runx2 is essential and sufficient to induce VSMC calcification, 13, 14 AKT activation-induced elevation of the Runx2 protein in the PTEN-deficient VSMC may predispose the cells to undergo osteogenic differentiation. As a result, the PTEN deficiency promoted calcification of the PTEN ∆/∆ VSMC cultured in osteogenic medium without any additional stimuli. Runx2-regulated osteogenic marker genes, including osteocalcin and collagen type I, 13, 14, 44 increased concurrently. This finding is also supported by the data from the in vivo studies with SMC-specific reduction of PTEN. Apparently, increased AKT activation by the PTEN reduction contributes to Runx2 upregulation and the spontaneous development of vascular calcification in these mice.
The elevated amount of Runx2 protein in the PTENdeficient VSMC under basal conditions was not caused by increased expression of Runx2 at the transcriptional level. Instead, the PTEN deficiency in VSMC stabilizes the Runx2 protein by inhibiting Runx2 degradation, an important mechanism that has been demonstrated to stabilize the Runx2 protein in bone cells. 38 In bone cells, post-translational modulation by the ubiquitin-proteasome pathway regulates stability and degradation of Runx2 protein. 39 Our studies have provided the first evidence that the PTEN deficiency increases the Runx2 stability by inhibiting ubiquitination of Runx2 in the PTEN ∆/∆ VSMC. Studies in osteoblasts have identified several molecules that contribute to Runx2 degradation, including Smad ubiquitin regulatory factor 1 and cyclin-D1. 45, 46 Smad ubiquitin regulatory factor 1 is an E3-ligase that binds to Runx2 and mediates ubiquitin binding to Runx2 that leads to Runx2 degradation. 45 Cyclin-D1, on the other hand, contributes to proteasome-dependent degradation of Runx2 by cyclin D1/Cdk4-induced Runx2 phosphorylation in the C-terminus of Runx2, which is critical for Runx2 protein stability. 46 Additionally, other factors have been implicated in mediating Runx2 degradation by recruiting E3-ligases, such as Smad 6, which binds to Runx2 and serves as an adaptor for Smad ubiquitin regulatory factor 1-induced Runx2 degradation. 47, 48 However, the PTEN deficiency in VSMC did not affect the expression of the previously characterized regulators of Runx2 ubiquitination in the bone cells, such as Smad ubiquitin regulatory factor 1 and cyclin-D1. Therefore, the molecular regulators that modulate Runx2 degradation and ubiquitination in VSMC may be novel, which warrant further exploration.
Our studies have also demonstrated that the FOXO1/3 signaling axis is responsible for the inhibition of the Runx2 ubiquitination, thereby upregulates Runx2 which then promotes VSMC calcification. Specifically, AKT-regulated phosphorylation and cytosolic translocation of FOXO1/3 uncreased Runx2 in VSMC. The phosphorylation and subsequent nuclear exclusion of the FOXO family of proteins has been associated with neointimal hyperplasia in a rat balloon injury model. 40 Upregulation of AKT/FOXO signaling has been found in the vasculature in an aging rat atherosclerosis model. 49 However, the function of SMC-expressed FOXO family proteins in regulating vascular calcification is unknown. Using FOXO1/3-specific small hairpin RNA, we determined that FOXO1/3 regulates upregulation of Runx2 and subsequent calcification of VSMC. FOXO1 and 3 have been found to increase Runx2 in osteoblasts and human embryonic stem cells; however, other studies indicate that FOXO1 inhibits the Runx2 activity in osteoblasts or prostate cancer cells. [31] [32] [33] [34] Our studies have delineated a novel function of FOXO1/3 in regulating the Runx2 protein stability in VSMC. Consistent with the cross-regulation of FOXO1/3 in human fibroblasts, 41 knockdown of FOXO1 decreases the expression of FOXO3 in VSMC and vice versa, implying a positive feedback loop controlling the expression of FOXO1/3. Knockdown of FOXO1/3 phenocopied the PTEN deficiency in terms of Runx2 ubiquitination and VSMC calcification, which support a novel function of FOXO1/3 in the process. More importantly, increased FOXO phosphorylation and Runx2 upregulation are associated with AKT activation in vascular calcification in the heterozygous SMC-specific PTEN deletion mice as well as the atherogenic ApoE −/− mice in vivo. Decreased Runx2 ubiquitination has been found in the vasculature of the HFD-fed ApoE −/− mice, which may lead to decreased Runx2 degradation and thus increase Runx2 and promote vascular calcification. These animal studies have further supported an important role of AKT activation, FOXO phosphorylation, and Runx2 ubiquitination in vascular calcification in vivo.
In summary, the current studies have demonstrated a causative effect SMC-specific PTEN deficiency on vascular calcification via activation of AKT and upregulation of Runx2 in vitro and in vivo. We have further determined a novel function of the AKT/FOXO1/3 signaling axis in regulating Runx2 ubiquitination and stability. These studies have provided the first evidence demonstrating the role of FOXO1/3 in mediating activation of AKT-induced VSMC calcification and identified that FOXO1/3-modulated ubiquitination of Runx2 as a novel mechanism in regulating vascular calcification. The new molecular insights gained in the present studies in the regulation of Runx2 in the development of VSMC calcification may lead to identification of novel therapeutic targets.
